Renovaro Biosciences Stock Buy Hold or Sell Recommendation
| RENB Stock | 0.61 0.09 17.31% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Renovaro Biosciences is 'Strong Sell'. Macroaxis provides Renovaro Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding RENB positions.
Check out Renovaro Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide. In addition, we conduct extensive research on individual companies such as Renovaro and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Renovaro |
Execute Renovaro Biosciences Buy or Sell Advice
The Renovaro recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Renovaro Biosciences. Macroaxis does not own or have any residual interests in Renovaro Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Renovaro Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Renovaro Biosciences Trading Alerts and Improvement Suggestions
| Renovaro Biosciences is way too risky over 90 days horizon | |
| Renovaro Biosciences has some characteristics of a very speculative penny stock | |
| Renovaro Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (80.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Renovaro Biosciences generates negative cash flow from operations | |
| About 50.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
Renovaro Biosciences Returns Distribution Density
The distribution of Renovaro Biosciences' historical returns is an attempt to chart the uncertainty of Renovaro Biosciences' future price movements. The chart of the probability distribution of Renovaro Biosciences daily returns describes the distribution of returns around its average expected value. We use Renovaro Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Renovaro Biosciences returns is essential to provide solid investment advice for Renovaro Biosciences.
| Mean Return | 0.25 | Value At Risk | -13.24 | Potential Upside | 17.31 | Standard Deviation | 9.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Renovaro Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Renovaro Stock Institutional Investors
| Shares | Citigroup Inc | 2024-09-30 | 61 K | Goldman Sachs Group Inc | 2024-06-30 | 59.1 K | Rhumbline Advisers | 2024-06-30 | 45.2 K | Alliancebernstein L.p. | 2024-06-30 | 37.9 K | Jane Street Group Llc | 2024-06-30 | 35.8 K | Bank Of America Corp | 2024-06-30 | 26.3 K | Corebridge Financial Inc | 2024-06-30 | 26.2 K | Msa Advisors Llc | 2024-09-30 | 25 K | Amvescap Plc. | 2024-06-30 | 23 K | Vanguard Group Inc | 2024-09-30 | 5.7 M | Blackrock Inc | 2024-06-30 | 3.7 M |
Renovaro Biosciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.6M) | 12.0M | (11.5M) | (7.3M) | (1.7M) | (1.6M) | |
| Free Cash Flow | (10.6M) | (20.7M) | (15.7M) | (11.8M) | (11.0M) | (11.6M) | |
| Other Non Cash Items | (200.6K) | 3.3M | (2.6M) | 995.8K | 56.1M | 58.9M | |
| Capital Expenditures | 184.5K | 48.9K | 5.2K | 29.8K | 70.4K | 96.9K | |
| Net Income | (11.4M) | (26.7M) | (113.4M) | (39.7M) | (80.7M) | (76.6M) | |
| End Period Cash Flow | 8.7M | 20.7M | 9.2M | 1.9M | 220.5K | 209.4K | |
| Depreciation | 366.3K | 123.5K | 123.6K | 113.5K | 121.9K | 106.6K | |
| Investments | (184.5K) | (48.9K) | (5.2K) | (29.8K) | (26.8K) | (28.1K) | |
| Change To Netincome | (140K) | 4.5M | 95.9M | 23.1M | 26.6M | 16.6M |
Renovaro Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Renovaro Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Renovaro Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Renovaro stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 1.44 | |
σ | Overall volatility | 9.63 | |
Ir | Information ratio | 0.01 |
Renovaro Biosciences Volatility Alert
Renovaro Biosciences is displaying above-average volatility over the selected time horizon. Renovaro Biosciences is a potential penny stock. Although Renovaro Biosciences may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Renovaro Biosciences. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Renovaro instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Renovaro Biosciences Fundamentals Vs Peers
Comparing Renovaro Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Renovaro Biosciences' direct or indirect competition across all of the common fundamentals between Renovaro Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Renovaro Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Renovaro Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Renovaro Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Renovaro Biosciences to competition |
| Fundamentals | Renovaro Biosciences | Peer Average |
| Return On Equity | -0.9 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Current Valuation | 100.47 M | 16.62 B |
| Shares Outstanding | 158.72 M | 571.82 M |
| Shares Owned By Insiders | 50.37 % | 10.09 % |
| Shares Owned By Institutions | 9.30 % | 39.21 % |
| Number Of Shares Shorted | 3.41 M | 4.71 M |
| Price To Book | 0.99 X | 9.51 X |
| EBITDA | (79.52 M) | 3.9 B |
| Net Income | (80.65 M) | 570.98 M |
| Total Debt | 3.79 M | 5.32 B |
| Book Value Per Share | 0.85 X | 1.93 K |
| Cash Flow From Operations | (10.97 M) | 971.22 M |
| Short Ratio | 4.72 X | 4.00 X |
| Earnings Per Share | (0.98) X | 3.12 X |
| Number Of Employees | 25 | 18.84 K |
| Beta | 0.54 | -0.15 |
| Market Capitalization | 96.86 M | 19.03 B |
| Total Asset | 163.13 M | 29.47 B |
| Retained Earnings | (324.68 M) | 9.33 B |
| Working Capital | (8.46 M) | 1.48 B |
| Net Asset | 163.13 M |
Note: Insider Trading [view details]
Renovaro Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Renovaro . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Renovaro Biosciences Buy or Sell Advice
When is the right time to buy or sell Renovaro Biosciences? Buying financial instruments such as Renovaro Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Renovaro Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beer and Liquor Thematic Idea Now
Beer and Liquor
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Beer and Liquor theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beer and Liquor Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Renovaro Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.